What is HC Wainwright’s Forecast for BBOT FY2026 Earnings?

BridgeBio Oncology Therapeutics, Inc (NASDAQ:BBOT) – Equities research analysts at HC Wainwright cut their FY2026 earnings per share estimates for shares of BridgeBio Oncology Therapeutics in a report released on Friday, May 1st. HC Wainwright analyst R. Burns now anticipates that the company will earn ($2.12) per share for the year, down from their prior estimate of ($2.07). HC Wainwright has a “Buy” rating and a $29.00 price target on the stock. The consensus estimate for BridgeBio Oncology Therapeutics’ current full-year earnings is ($2.18) per share. HC Wainwright also issued estimates for BridgeBio Oncology Therapeutics’ Q4 2026 earnings at ($0.55) EPS.

Several other brokerages also recently commented on BBOT. Weiss Ratings started coverage on BridgeBio Oncology Therapeutics in a research note on Wednesday, January 14th. They issued a “sell (d+)” rating for the company. Stifel Nicolaus started coverage on BridgeBio Oncology Therapeutics in a research note on Tuesday, February 10th. They issued a “buy” rating and a $23.00 price objective for the company. Finally, Raymond James Financial raised BridgeBio Oncology Therapeutics to a “moderate buy” rating in a research note on Friday, January 9th. Three analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, BridgeBio Oncology Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $26.00.

BridgeBio Oncology Therapeutics Trading Up 0.8%

BBOT stock opened at $8.46 on Tuesday. The business’s 50 day moving average price is $9.27. BridgeBio Oncology Therapeutics has a fifty-two week low of $8.00 and a fifty-two week high of $14.87. The firm has a market cap of $677.73 million, a P/E ratio of -5.57 and a beta of 0.22.

Institutional Investors Weigh In On BridgeBio Oncology Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. CIBC Private Wealth Group LLC bought a new stake in shares of BridgeBio Oncology Therapeutics in the 4th quarter valued at about $63,000. Persistent Asset Partners Ltd bought a new stake in shares of BridgeBio Oncology Therapeutics in the 4th quarter valued at about $107,000. Squarepoint Ops LLC bought a new stake in shares of BridgeBio Oncology Therapeutics in the 4th quarter valued at about $144,000. Quadrature Capital Ltd bought a new stake in shares of BridgeBio Oncology Therapeutics in the 4th quarter valued at about $162,000. Finally, BIT Capital GmbH bought a new stake in shares of BridgeBio Oncology Therapeutics in the 4th quarter valued at about $313,000. Institutional investors own 54.89% of the company’s stock.

About BridgeBio Oncology Therapeutics

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) is a publicly traded biotechnology company focused on discovering and developing therapies for cancer. The company concentrates on translating scientific insights into clinical-stage programs aimed at addressing oncology indications with unmet medical need.

BridgeBio Oncology’s activities center on research and development of investigational therapeutics, advancing drug candidates through preclinical studies and clinical trials. Its work typically involves in-house discovery efforts and collaborations with academic and industry partners to identify targets, optimize compounds, and generate the clinical data needed to support regulatory development.

Public information about BridgeBio Oncology Therapeutics’ specific programs, geographic operations and leadership is limited in the sources available here.